Richard G. Bach

Richard G. Bach, MD, FACC

  • Cardiology

Sees Patients For

Interventional cardiology, coronary angioplasty, atherectomy and stenting, valvuloplasty, peripheral intervention, percutaneous atrial septal defect closure, transcoronary alcohol septal ablation for HCM, cardiac catheterization hypertrophic cardiomyopathy with obstruction, coronary ultrasonographic and physiologic assessment, cardiac critical care

Referral Type

Physician Referral Required

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital

Board Certifications

  • Interventional Cardiology
  • Cardiovascular Disease
  • Internal Medicine

Academic Title(s)

Professor, Medicine
Division of Cardiovascular Diseases
Director, Cardiac Intensive Care Unit

Languages

  • English

Education

Fellowship

1991 Cardiac Catheterization and Angioplasty, NYU Medical Center Bellevue Hospital, New York, New York

Fellowship

1990 Clinical, Cardiology, New York University Medical Center Bellevue Hospital, New York, New York

Fellowship

1988 Research, Cardiology, New York University Medical Center, Bellevue Hospital, New York, New York

Residency

1987 Medicine, New York University School of Medicine, New York, New York

Medical Degree

1984 New York University School of Medicine, New York, New York

B.S.

1977 Biological Sciences, Georgetown University, Washington D.C.

Research Interests

Clinical investigation in acute coronary syndromes: In the cardiac intensive care unit, my group has focused on the clinical investigation of outcomes and promising therapies for patients with acute myocardial infarction (AMI) and acute coronary syndromes (ACS).  Coronary intervention and coronary physiology: Another of my primary research interests involves interventional cardiology, with pre-clinical and clinical studies in the use of magnetic navigation via the Stereotaxis Niobe system to facilitate coronary intervention; Hypertrophic cardiomyopathy: For symptomatic patients with left ventricular outflow tract obstruction due to hypertrophic obstructive cardiomyopathy, a catheter-based method of non-surgical septal reduction by alcohol septal ablation can provide significant symptomatic improvement. To better understand the short and long-term benefits of transcatheter alcohol septal ablation, we are studying its effects on cardiac remodeling and coronary and myocardial physiology. In addition, via collaborative translational echocardiographic and genetic studies, we are interested in exploring the gene polymorphisms that contribute to the wide phenotypic anatomic and physiologic variability among patients and family members with hypertrophic cardiomyopathy

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: RocheRoyalties: $1 - $9,999Consulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: Eli LillyRoyalties: $1 - $9,999Consulting/Advisory Board: $10,000 - $19,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: NovoNordiskRoyalties: $1 - $9,999Consulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: SunovionRoyalties: $1 - $9,999Consulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: PharmacosmosRoyalties: $1 - $9,999Consulting/Advisory Board: $20,000 - $39,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: NovoNordisk-QuintilesRoyalties: $1 - $9,999Consulting/Advisory Board: $40,000 - $59,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: Pharmacosmos-ParexelRoyalties: $1 - $9,999Consulting/Advisory Board: $100,000 - $149,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021